

Review

Unraveling molecular determinants of manual therapy: an approach to integrative therapeutics for the treatment of fibromyalgia and CFS/ME

José Andrés Espejo^{1‡}, María García-Escudero^{2‡} and Elisa Oltra^{3,4*}

¹School of Experimental Sciences, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain

²School of Physiotherapy, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain

³School of Medicine, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain

⁴Unidad Mixta CIPF-UCV, Centro de Investigación Príncipe Felipe, Valencia, Spain

* Correspondence: elisa.oltra@ucv.es; Tel.: +34-963-637-412

Abstract:

Application of protocols without parameter standardization and rigorous controls has led manual therapy (MT) and other physiotherapy approaches to controversial outcomes. Thus, there is an urgency to carefully define standard protocols that elevate physiotherapy treatments to rigorous scientific demands. One way this can be achieved is by studying gene expression and additional physiological changes that associate to particular, parameter-controlled, treatments in animal models and translating this knowledge to properly design objective, quantitatively-monitored clinical trials. Here, we propose a Molecular Physiotherapy Approach (MPTA), requiring multidisciplinary teams, to uncover the scientific reasons behind the numerous reports of MT that historically attribute benefits to these treatments. The review focuses in the identification of MT-induced physiological and molecular responses that could be used for the treatment of fibromyalgia (FM) and CFS/ME. The systemic effect associated to mechanical-load responses is considered of particular relevance as it suggests that defined, low-pain areas could be selected for treatments with overall benefits, an aspect that might result essential to treat FM. Additionally, MT can provide muscle conditioning to sedentary patients without demanding strenuous physical effort, detrimental for CFS/ME patients, placing MT as a real option for integrative medicine programs to treat FM and CFS/ME.

Keywords: Fibromyalgia; CFS/ME; manual therapy; integrative medicine; physiotherapy

1. Introduction

Fibromyalgia (FM), according to the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) M79.7, including Fibromyositis, Fibrositis and Myofibrositis, is defined as a chronic disorder of unknown etiology characterized by low pain threshold, stiffness and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs, usually accompanied by headaches, fatigue, sleep disturbances, memory loss and painful menstruation [1-4]. Patients present inflammation and fibrous degeneration of muscles [1]. Similarly, Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) (ICD-10-CM R53.82 or G93.3 if post-viral) is defined as an acquired complex multisystem disease with characteristic clinical features that include exercise-induced fatigue, post-exertional malaise (PEM)/symptom exacerbation, cognitive dysfunction, orthostatic intolerance, on-going flu-like symptoms and unrefreshing sleep in conjunction with other [5,6]. Often FM and CFS/ME show overlapping symptoms as FM patients experience chronic fatigue and CFS/ME suffer from muscle tenderness and pain, and thus, some authors have posited they are part of the same somatic syndrome [7,8]. In support of this hypothesis a recent analysis by Nathelson et al., reports increased ventricular cerebrospinal fluid lactate levels

in patients of CFS/ME, FM or both, with respect to healthy participants [9]. However, differences across a number of clinical and biological parameters, such as PEM and autonomic function [10-12], hormone system unbalance [13,14], gene expression and cytokine profiles [15], and blood microRNA levels [16-19], suggest that the underlying pathophysiology in FM may differ from that of CFS/ME.

Current pharmacological treatments for patients suffering from FM and/or CFS/ME are mainly directed to palliate some symptoms [20-22], as clinical trials have failed to conclusively provide overall benefits together with no associated harms. Some treatments, however, seem to support significant improvement for certain patient subgroups. This seems to be the case for the N-methyl-D-Aspartate (NMDA) antagonist memantine [23] or the dopamine 3 receptor agonist pramipexole [24] for the treatment of FM and the anti-CD20 antibody Rituximab directed to B-cell depletion [25] for treatment of CFS/ME. In this last case, caution is recommended as *in vitro* treatment of NK cells with the agent leads to significant decreases in NK lysing activity and a significant increase in cell degranulation, suggesting that Rituximab may be toxic for NK cells [26]. A more promising option for the treatment of CFS/ME is provided by the clinical trials of the Toll-like Receptor TLR-3 agonist rintatolimod (Poly I: C(12)U) which activates interferon induced proteins, showing medically significant improvement in the cohort of participating patients [22,27].

Alternative, non-pharmacological therapeutics, have also been extensively studied. Cognitive Behavioral Therapy (CBT) seems to lead to small benefits over control interventions in reducing pain, negative mood and disability at the end of treatment and at long-term follow-up in FM patients, as reported by 23 randomised controlled trials including 1073 patients receiving CBT and 958 patients in control groups [28]. Although mindfulness meditation may be helpful in improving pain perception it does not suffice for patients to recover their previous daily activity. Another non-pharmacological option is provided by Gradual Exercise Therapy (GET). FM patients are able to engage in moderate to vigorous exercise, however, they experience difficulties performing and adhering to even moderate intensity regimes because of increased FM symptoms associated to exercise [29]. In the case of CFS/ME patients, benefits from CBT/GET therapy have also been reported by clinical trials (PACE) including 160 participants per group compared to Specialist Medical Care (SMC) alone or Adaptive Pacing Therapy (APT) which did not show improvement [30]. Authors also claim that the beneficial effects were maintained at 1 year at long-term follow-up with a median of 2.5 years after randomisation [31]. However, serious concerns have been raised regarding inappropriate case definition of enrolled participants, scores that do not support significant improvement of fatigue and physical functioning at long-term and data indicative of subjective improvement by specialist medical care and APT to the same level as by CBT and GET, without any additional therapies [32,33], which questions the PACE trial outcomes as reported.

Even if exercise, which has shown promise in treating symptoms of centralized pain [34], could benefit FM and CFS/ME patients, the fact that exercise induces muscle pain and triggers exacerbated malaise in CFS/ME patients, makes this option unfit for these patients. Physiotherapy-based treatments, such as manual therapy (MT), on another end, might help providing exercise-like effects on treated tissues, as for example, increasing blood flow and/or muscle tone, without any physical activity demand from the patient, and thus, contrary to GET, should not compromise patient's health. At the same time, and similarly to CBT, MT might engage patient's mind into relaxation, boosting happiness.

To date, MT protocols, as most physiotherapeutic treatments, are poorly defined and yet, some clinical trials report benefits for massage therapy. For example, a systematic review and meta-analysis of Randomized Clinical Trials (RCTs) by Li, Yuan et al., show that MT with duration \geq 5 weeks shows improvement in pain, anxiety and depression in FM patients [35,36]. MT also seems to lead to positive effects on physical symptoms in CFS/ME, including depression, fatigue, pain and

insomnia [37-39], suggesting that MT could be used for therapeutic purposes by itself or in combination with current symptomatic pharmacology as part of integrative medicine programs.

The purpose of this review is to allocate potential mechanism rationale of MT for the effective treatment of FM and CFS/ME, capable of managing the symptoms that compromise daily activities in these patients. Towards this end, we reviewed mechanistic evidence, including preclinical data from animal models, and identified molecular changes associated to MT treatments that could improve immune, cognitive and muscular dysfunctions on one side and alleviate pain on another, in an effort to build standardized therapeutic MT protocols to treat patients affected of FM and/or CFS/ME.

Our proposal is that future MT studies for the treatment of FM and CFS/ME are designed on the basis of quantitative objective traits associated to rigorously defined protocols. The efficacy of the treatments to be assayed in Clinical Trials (CTs) for validation of effects and optimization of parameters before being translated to the Clinic, must demand close control of selected molecular or other disease-associated quantitative markers to objectively track individual response of FM and CFS/ME patients to received treatments.

2. Molecular determinants of MT: lessons from animal models and mimetic devices

MT comprises a set of therapies based on the manual manipulation of joints and soft tissues, with the purpose of relieving pain, reducing inflammation, eliminating muscular contractures, increasing range of motion (ROM), facilitating movement, etc. and ultimately, restoring health. It covers a very diverse range of techniques such as massage, muscular stretching, manipulations and mobilizations among others.

Stretching strategies and protocols are widely used to improve flexibility or maintain health, acting on the muscle tendon-unit, in order to improve the ROM of joints [40]. Due to our final purpose: treatment of main symptoms in FM and CFS/ME patients with standardized effective protocols, we will concentrate our attention on the available evidence for passive muscle stretching, defining it as a MT procedure effected by a professional physiotherapist on the patient.

The other variant of MT that will be covered in this review is massage. Massage has been defined by Cafarelli and Flint, as a mechanical manipulation of body tissues with rhythmical pressure and stroking for the purpose of promoting health and well-being [41]. It is applied on soft tissues: skin, muscle and conjunctive or connective tissue sometimes with the help of mechanical or electrical devices to pursue various purposes, therapeutic included. There are different massage maneuvers (rubbing, friction, kneading, pressures, percussions and vibrations) in relation to variables such as duration, frequency, repetitions or pressure. Different benefits have been attributed to various massage maneuvers, for example, massage with moderate pressure seems to increase vagal tone and also be key for stimulating subcutaneous mechanoreceptors that send pain relief signals to the brain and release de-stressing neurochemicals, such as serotonin and dopamine [42,43].

MT treatments are associated to mechano-transduction, a general biophysical process by which cells are capable of sensing their physical environment and translating those cues into biochemical signals such as shifts in intracellular calcium concentration, alteration of gene expression profiles and induction or repression of signaling pathways that finally lead to morphological and/or physiological changes [44,45], which may lead to therapeutic effects.

We hypothesize that knowledge of the parameter-dependence that MT programs induce on treated tissues, at the molecular level, should allow for the development of rigorous and standardized effective protocols (Molecular Physiotherapy Approach or MPTA) that provide health

benefits to FM and CFS/ME patients. An initial step to acquire this knowledge on the MT-treated tissues involves evaluating profiles of gene expression of healthy tissues before and after particular, carefully defined, procedures.

Methodological limitations apply to these studies with human subjects related not only to ethical concerns for sampling but also to application of the technique, such as the amount of load applied, and frequency and duration of sessions. To overcome these limitations preclinical animal trials with mimetic devices need to be performed to identify molecules or biological patterns of interest in the target tissue in first place and, optimally, translate the identified markers to a liquid biopsy test for human CTs monitorization. With this final goal, we proceed to summarize the molecular information of MT treatments in animal models that might be of relevance for the treatment of FM and CFS/ME underneath.

2.1. Neuroimmune impact of MT

A group of researchers led by Dr. Dupont-Versteegden, has objectively shown the effects of massage on healthy, unperturbed skeletal muscle on the modulation of key immune cells involved in the inflammatory response. For that purpose, the authors used Wistar rats (N=24) and performed histological and microarray analysis on the tibialis anterior muscle after cyclic compressive loading (CCL). They used a custom-fabricated massage mimetic device to standardize and control the amount of load applied, the frequency and duration of sessions. The instrument consists of a spring-load mechanism allowing a cylinder (the load) to press and roll over a mass of tissue with an oscillating movement. Treatment for 30 minutes, once a day, for 4 consecutive days, using different loading conditions (1.4 to 11N), showed load-dependent molecular and cellular abundance changes of CD68⁺ and CD163⁺ subpopulations, with respect to sham loading controls. Moreover, load-independent changes were also evidenced on the non-CCL treated contralateral limb, indicating a systemic response of the massage-mimetic treatment [46]. From the 47% of the functional gene ontology clusters associating with immune response after CCL, the authors validated the chemokine (C-C motif) receptor CCR2, a critical regulator of skeletal muscle regeneration [47,48]; the leukocyte immunoglobulin like receptor B4 (Lilrb4), alias ILT3, thought to control inflammatory responses and limit autoreactivity through Treg enhancement [49]; the major histocompatibility complex (class II) molecule Cd74, an important regulator of immunity and inflammation with an impact on the cell endosomal compartment [50]; and the lysozyme 2 (Lyz2) gene involved in activities such as reducing the presence of proinflammatory cytokines (TNF- α , IL-6, INF- γ , IL-8 and IL-17) while increasing levels of anti-inflammatory cytokines (IL-4 and TGF- β) [51]; by the cost-effective alternative approach RT-qPCR (real time polymerase chain reaction after retrotranscription) which entitles a rather easy implementation of molecular marker monitorization in follow-up studies. All these molecular changes appeared unaffected in low load treatments (1.4 N) and upregulated by medium load treatments (4.5 N) indicating that a minimum pressure is required to register the effect. High load treatments (11 N) showed extracellular edema and different patterns that fit with induced muscle damage.

In rats CD68⁺ and CD163⁺ macrophage subpopulations correspond to pro-inflammatory (M1) and anti-inflammatory (M2) subtypes, formerly known as ED1⁺ and ED2⁺, respectively. Macrophages expressing pro-inflammatory M1 markers preferentially associate with proliferating muscle-precursor satellite cells, whereas macrophages mainly express anti-inflammatory M2 phenotype on myogenic differentiation stages [52]. This, together with the fact that CCR2 null mice display retarded inflammatory process and deficient muscle regeneration characterized by poor macrophage recruitment and adipocyte infiltration [47,48,53], suggests that in fact the CCL treatment studied by Waters-Banker et al. induces muscle regeneration.

Another study in C57/BL6 mice reports that massage-like stroking boosts thymic and splenic T cell numbers with statistical significant changes in double positive CD4⁺ CD8⁺ T-cells, as well as in single positive CD4⁺ or CD8⁺ cells. This increase in cell counts was correlated with decreased noradrenaline levels and reduced noradrenergic nerve fibers of thymus and spleen, possibly mediated by catecholamines, even partially reverting the immunosuppressive effect of hydrocortisone on CD4⁺ CD8⁺ T cells [54], indicating that massage may support recovery of immune function in individuals affected with immunodepression.

The group led by Yokota, on another side, used a commercial knee electro-mechanical loading system (ElectroForce 3100, Bose Corporation, Eden Prairie, MN) which applies lateral loads to the knee to induce anabolic responses in the skeleton [55,56] to study the effects of this treatment in rat brains [57]. The rationale behind their hypothesis derived from the observation that physical activities, regularly involving application of a mechanical load on the skeleton, seem to have a stimulatory role in pain control, neural regeneration and synthesis of neurotransmitters [58-60]. The authors show by using RT-qPCR, western-blot and immunohistochemistry analysis, that knee

loading of 1 N at 5Hz for 1500 cycles and a 5 minute treadmill running (positive control) upregulated mRNA levels of tryptophan hydroxylase 2 (tph2) in the raphe nuclei of brain stem, the site of serotonin synthesis in the brain, in reference to sham load and 90 minute tail suspension (stressed negative control) [57]. In addition, these authors showed that the mRNAs encoding two transcription factors of the Tph2 gene (Sim1 and Pet1) were significantly upregulated by this knee-loading treatment as well [58]. Reduced serotonin or tph2 expression have been linked to depression, schizophrenia and Alzheimer's dementia associated neurodegeneration [61-63], suggesting that restoration of serotonin levels through mild knee-loading may have therapeutic effects for these disorders.

2.2. Effects of MT in muscle regeneration

In 2016 the group led by David J. Moone evaluated biphasic ferrogel-driven cyclic mechanical compressions, driven by external magnets, as an alternative to biomaterial-based delivery of myogenic (insulin-like growth factor or IGF), fibroblast growth factor-2 (FGF-2), hepatocyte growth factor (HGF) and the angiogenic vascular endothelial growth factor (VEGF) regeneration of severely injured muscle [64,65]. The study was based on the observation that skeletal muscle and satellite cells are sensitive to biophysical micro environmental cues, such as mechanical loading and stretch-associated progenitor activation [66,67]. The treatment consisted on stimulations at 1 Hz for 5 minutes every 12 h by approaching and retracting a magnet to the tibialis anterior muscle subcutaneously implanted ferrogel on a murine model of myotoxin-induced or hind limb ischemia. Damaged muscle in these models lead to substantial muscle necrosis, fibrosis and contractile function loss if left untreated. The results showed that, 2 weeks after treatments, mice presented greater mean muscle fiber size than the untreated and an approximate 3-fold increase in maximum contractile force, indicative of effective muscle regeneration. Interestingly, the effect involved only the treated extremity and led to a reduction of M1 macrophages in the tissue, suggestive of a potent immune modulatory role for cyclic mechanical compressions. This treatment induced a temporary increase in intramuscular oxygen concentration which remained elevated until stimulation ceased. However, angiogenesis remained unaffected by the treatment according to unaltered average capillary density in muscle sections and no differences were observed for the endothelial marker CD31 [64].

Also recently the group of Dupont-Vergesteegden used their CCL device (4.5 N load at 0.5 Hz frequency for 30 min every other day for four bouts during a regrowth period of 8 days) on hindlimb unloaded Fischer-Brown Norway rats, finding that the CCL treatment applied induced an anabolic response in muscles helping them regrow after an atrophy-inducing event. These authors conclude that massage can be used as an intervention to aid in the regrowth of muscle lost during immobilization, thus, MT-based programs that include medium load pressure may help recover muscle mass in sedentary deconditioned individuals such as patients severely affected of FM and/or CFS/ME. Interestingly, they also found that the contralateral non-massaged limbs exhibited a comparable 17% higher muscle fiber size compared to reloading alone suggestive, as formerly observed for other markers, of a systemic effect of CCL. The authors indicate that the mechanism could, at least in part, be mediated by the presence of Pax7+ cells induced by the CCL treatment [67].

Pax7 expression, a satellite cell marker and transcription factor associated to muscle differentiation, is regulated by microRNA-431 in that tissue. Interestingly enough, miR-431 attenuates the muscular dystrophic phenotype in *mdx* mice (a model of Duchenne muscular dystrophy) and has been proposed as a potential therapeutic target in muscular diseases [68]. In addition, miR-431 is a key post-transcriptional regulator for axon regeneration, during neural development, for brain function, and in neurological diseases [69], although this aspect has not yet been explored in relation to MT. Also, Pax7's function is conditioned by post-transcriptional modifications such as SUMOylation [70]. Further work is required to more clearly understand the link between MT therapeutic effects and this molecular marker.

MicroRNAs currently comprise a collection of 4690 unique small RNA sequences (miRbase v22) of 20-24 nucleotides that work as epigenetic regulators of gene expression, mainly by inducing degradation of their target mRNAs [71,72]. Their stability and potential to control different targets has attracted their study as potential sensors of biological processes and, thus, as biomarkers of disease. The fact that molecular alterations precede physiological and morphological changes in the cell and that miRNAs can be accurately quantitated by relatively easy cost-effective methods should make them attractive candidates to objectively evidence the impact of MT on the treatment of FM and CFS/ME.

In trend with the knowledge that cells sense their physical environment and that the physical application of forces translate into changes of patterns in gene expression [44,45], those miRNAs that are mechanosensitive, meaning their levels appear regulated by mechanical cues, have been coined as mechanomiRs [73]. Although the role of cytoskeletal proteins in force transmission and mechanotransduction is quite well established [73, 74], there is a paucity of knowledge regarding mechanosensitive gene regulatory networks.

The group of Aladin M. Boriek used the mouse *mdm* (muscular dystrophy or MD with myositis) model to identify gene regulatory networks in normal and defective organisms using an *ex-vivo* model of mechanical stretch (passive stretching of approx. 0.4 N/cm in the longitudinal or transverse direction to the muscle fibers), as that information could lead to novel therapeutic approaches for MD. Their genome-wide microarray results show a list of anisotropic regulated mechanomiRs which interestingly grouped into clusters of bicistronic or polycistronic transcriptional units from close genomic loci (<10 kb) suggesting that these mechanomiRs may present similar or coordinated biological functions [73]. In addition, the authors also found that the stretch applied significantly altered the microRNA synthesis and processing machinery. In particular, they found that stretching upregulated the nuclear protein Drosha, the cytoplasmic factor Dicer, the microRNA export protein exportin-5, and Argonaut proteins (1-3 and 5) both in wild type (WT) and *mdm* mice, while not affecting the levels of the DiGeorge syndrome chromosomal region 8 (DGR8). Moreover, the overall levels of expression of these components of the miRNA machinery were significantly higher in *mdm* than in wt (wild type) individuals [73], suggesting a higher sensitivity of this machinery to mechanical stress in neuromuscular disorders.

Other authors have identified individual mechanomiRs and demonstrated their role in human disease, as it is the case of miR-146a which regulates mechanotransduction and pressure induced inflammation in cultured human small airway epithelium [75], miR-126 which has been linked to angiogenesis [76], the let-7 family of miRNAs associated to aging and cancer [77], whose down-regulation, together with miR-98-5p may compromise satellite cell proliferation and muscle regeneration capacity [73]. Interestingly some of these mechanomiRs are expressed in non-skeletal muscles, opening the possibility for liquid biopsy testing of patients subjected to MT. Caution in interpretation of miRNAs levels is advised as their regulatory function will depend on the cell target and their role is not limited to down-regulating the mRNA of target genes.

2.3. MT impact on the nervous system and on pain relief

Since the first animal model of nociception was described in the XIX century [78], many interventions and strategies have been used to simulate the mechanism of injury, comprising mechanical, thermal, neuropathic, inflammatory or other) on the affected tissue. For example neuropathic models are generated by spinal nerve ligation surgery, chronic constriction or sciatic nerve injury, while inflammatory pain is usually reproduced by injection of different substances such as capsaicin or Freund's complete adjuvant (CFA) or the irritant carrageenan. For a comprehensive compilation on animal models of pain we refer the readers to the review by Gregory et al. [79]. More recently, rodent models that mimic the signs and symptoms of FM, including long lasting hyperalgesia without overt peripheral tissue damage [80] and also CFS, including mechanical

allodynia and hyperalgesia without signs of inflammation and injury but activated microglia [81], have been developed. While a variety of methods such as repeated muscle insults with acid injections, depletion of biogenic amines, and stress were used for the first, a multiple continuous stress of housed in a cage with a low level of water (1.5 cm in depth) was used for the second [80,81].

The relationship between miRNA expression profiles and chronic pain has been studied in animal models at different levels: at the peripheral sensory neuron level, with soma in the dorsal root ganglion (DRG) and their axons in the skin and other organs; in the spinal cord dorsal horn (SDH) level, where secondary neurons receiving nociceptive stimuli from the periphery send them to the brain; and at the level of different parts in the brain.

Following this order, from peripheral perception to brain, we find the study of Aldrich et al., in 2009 who using a modified version of the spinal nerve ligation (SNL) model in rat, in which only the L5 spinal nerve was ligated, they found a sensory organ-specific cluster of miRNAs including miR-96, miR-182, and miR-183 that were highly enriched in the DRG. The levels of all 3 miRs in this cluster appeared significantly reduced in injured DRG neurons. Moreover, their uniform distribution within the DRG soma of non-allodynic animals was changed in allodynia where they preferentially localized to the periphery of neurons [82]. The redistribution of these miRNAs followed the pattern in the distribution of the stress granule protein T-Cell Intracellular Antigen 1 (TIA-1) and could be associated to nerve damage. Lin et al., later confirmed that SNL-induced mechanical allodynia is significantly correlated with a decreased expression of miR-183 in DRG cells, and showed that intrathecal administration of lentivirions expressing miR-183 downregulated SNL-induced increases in the expression of Nav1.3 and brain-derived neurotrophic factor (BDNF), correlating with significant attenuation of SNL-induced mechanical allodynia [83].

On another side, Tam Tam et al., showed that miR-143 expression levels were significantly reduced in DRGs ipsilateral to CFA injection or after nerve damage [84], coinciding with our findings that miR-143 is down regulated in PBMCs of patients of FM suffering of chronic fatigue [16]. This miR, however, has been reported to be upregulated in plasma of CFS/ME patients [19]. It should be pointed out that the differences found across different pain models suggest the existence of disorder specific miRNAs rather than common miRNA regulators of nociceptive modulation. For example, members of the miR-34 family are strongly underexpressed following neuropathic pain induction while appears highly overexpressed following bone metastatic pain induction in DRG [85,86]. Also, it has been described that the interactions between sensory neurons and non-neuronal cells such as immune cells and microglia modulate nociceptive sensitivity [87] and therefore changes in other cells of the body, such as blood cells, might be indicators of individual changes in nociceptive thresholds, even if the alteration pattern of the deregulated microRNAs does not match with that in the tissue affected they might still serve as reporters. This is particularly relevant as it opens the possibility of a liquid biopsy to detect and monitor nociceptive sensitivity.

Interestingly enough, the mechano-miR 146a that has been reported among the list of miRs that are deregulated in CFS/ME [88], appears upregulated in synovial tissue of rheumatoid arthritis patients, in cartilage of osteoarthritis patients and in human monocytic cell lines after lipopolysaccharide (LPS) proinflammatory stimuli [89-91] while it appears downregulated, both, in the ipsilateral DRG and at the SDH level [92].

Other miRNAs linked to FM and CFS/ME, in particular miR-21 and miR-223, also associate to pain in animal models [16,88,93]. While both miRs are increased in spinal cord after spinal cord injury, the second also increases in the prefrontal cortex of the brain in a model of carrageenan induced facial inflammatory pain. Importantly the increase of miR-223 coincides with the peak of mechanical hyperalgesia, suggesting a role of this miR in the process [94-96]. Regarding deregulation of miR-21 and its connexion to pain mechanisms we should point out that Simeoli et al., have recently shown that primary cultured DRG neuron cell bodies release extracellular vesicles

(EVs), including exosomes, loaded with miR-21 upon capsaicin activation of TRPV1 receptors. These miR-21 loaded vesicles are readily phagocytosed by macrophages inducing a pro-inflammatory phenotype. Moreover, intratecal delivery of an antagomir of miR-21 or its conditional deletion in sensory neurons lower neuropathic hypersensitivity and inflammatory macrophage recruitment to the DRG indicating that the induction of miR-21 expression and its release contributes to sensory neuron-macrophage communication after peripheral nerve damage [97].

Since some of the miRNAs associated with pain initiation and maintenance have also been classified as mechanomiRs [73], it seems logical to think that MT might have an impact on their expression profiles. Perhaps it is through regulation of mechanomiR levels that MT exerts at least some of the attributed analgesic effects [98].

3. Rationale for using MT to treat FM and CFS/ME dysfunctions

A systematic review and meta-analysis of nine randomized controlled trials (RCT) including 404 FM patients has concluded that MT with duration of at least 5 weeks has beneficial immediate effects on improving pain, anxiety and depression in these patients [35]. While some previous reviews of the effect of MT for the treatment of FM symptoms coincide with this report, by concluding that MT provides benefits to FM patients [99,100], other showed negative [101] or inconclusive [102,103] results. However many of the studies included in these reviews were only qualitative in nature or constituted preliminary pilot studies including a small number of participants. Li et al., argue as possible explanation of their findings that their review included a larger number of RCTs and that their analysis contemplated subgrouping based on different durations of MT [35].

In addition, a systematic review and meta-analysis including sixty high-quality and seven low-quality RCT indicates that MT effectively treats pain and it is also beneficial for treating anxiety in the general population [104]. Another study of the same type, including a total of 140 studies, claims that MT is the most powerful method for reducing DOMS (delayed onset muscle soreness) and fatigue after exercise, compared to compression garment, electrostimulation, stretching, immersion or cryotherapy [105]. The authors observed a moderate decrease in the muscle damage marker creatine kinase (CK) and in the inflammation markers interleukin-6 (IL-6) and C-reactive protein.

On another side, the analysis of biopsied quadriceps (*vastus lateralis*) from 11 male volunteers showed that MT reduces inflammation after exercise-induced muscle damage by activating the mechanotransduction signaling pathways focal adhesion kinase or FAK and extracellular signal regulated kinase (ERK) 1/2, inducing mitochondria biogenesis signaling and by diminishing the levels of the inflammatory cytokines TNF- α and IL-6 and the stress factor HSP27 [106], changes that could benefit FM and CFS/ME patients [107,108]. Combinations of MT and stretching have also been studied, showing a significant reduction in fatigue with faster and shorter reduction of fatigue in females [109].

Among the models that have been developed to explain the physiopathology of FM and CFS/ME, one, at least partly, seems to set some basis for a potential impact of MT treatments in, not only alleviating symptoms, but also on delaying the progress of the disease: the neuromuscular strain model described by Rowe et al., [110]. These authors propose that “neuromuscular strain”, defined as an adverse neural tension and strain in muscles, fascia and other soft tissues, acts as a contributor to cognitive and other symptoms in CFS [111]. If the ability of the nervous system to undergo accommodative changes in length as a response to the habitual limb and trunk movements is impaired by restriction of movements, the mechanical tension within nerves increases leading to neurodynamic dysfunction, these authors argue. This dysfunction contributes to pain and other symptoms that CFS patients present with by processes of mechanical sensitization, altered nociceptive signaling, and reduced intra-neural blood flow, adverse patterns of muscle force and

contraction, plus inflammatory neuropeptide release. Supportive of this model is the preliminary work that the authors show of a longitudinal study of 2 years in 55 CFS patients showing that neuromuscular restrictions are common in CFS [110]. In addition these same authors show that longitudinal strain applied to nerves and soft tissues of the lower limbs is capable of increasing symptom intensity in individuals with CFS [111], supporting their model. If these neuromuscular strains are left untreated, the individual will adapt to increased symptom burden leading to increased impairment and central sensitization. The interventions recommended by these authors to prevent symptom aggravation are MT, exercise-based approaches or alternative therapies such as yoga or Tai Chi. In fact they report clinical improvement of patients by MT approaches [110]. This model seems to indicate that an action to release neural tensions at early stages of the disease might be most effective.

When MT is applied to soft and connective tissues, local biochemical changes (lactic acid, adenosine triphosphate or ATP and creatine phosphate or CP) occur, and local muscle blood and lymph circulation increase; as result local nociceptive and inflammatory mediators may be reabsorbed [112]. Other types of compressive treatments, such as neuromuscular taping, which also increases lymphatic and vascular flow, strengthening weakened muscles, have identified a panel of miRNAs that show changes associated to the treatment in a multiple sclerosis (MS) patient [113], some of which have been shown to appear deregulated, both, in FM [16,93,114] and in CFS/ME patients [88].

MT improves pain by modulation of serotonin levels in patients with CFS/ME and FM [43, 115] changing neural activity at the segmental level, area responsible for mood and pain perception [116]. MT delivery could result in reduction of the H-reflex with pressures as low as 1.25 kPa which would be desirable for FM patients as spinal hyper-excitability associates with a variety of chronic pain syndromes [117, 118]. On another side, myofascial stretching transduces into electro-physiologic activity that could reduce pain and other symptoms through myofascial communication and also through afferent neural pathways that modulate the subcortical nuclei and limbic system in the brain [119]. MT reduces circulating cortisol levels [43] and increases β -endorphin levels following a 30 minute-massage [120] which could explain reductions in perceived fatigue following MT.

Interestingly, Roberts has evaluated not only the magnitude of loading in MT but also the pattern applied, in particular, he tested three different levels of pressure in two different orders (increasing and decreasing) by using electromyography to measure muscle activity, finding that the physiological response of the muscle, in fact, depends on the pattern of applied pressures during massage as only the decreasing pattern altered the electromyographic recordings [121]. That finding, according to the author, is consistent with a mechanism by which light or moderate pressure massage may reduce the gain of spinal nociceptive reflexes, typically elevated in chronic pain syndromes.

With respect to musculoskeletal deconditioning or muscle atrophy associated to long periods of inactivity which often affects CFS/ME and some FM patients, especially severe cases, Rullman et al., have shown by replicating microgravity unloading through 21 days of sustained bedrest and hypoxia, that the majority of miRNAs that become deregulated belong to miRNA families that respond to mechanical loads (mechano-miRs) [73,122]. Interestingly, some of these miRs associated to microgravity unloading appear to be deregulated in FM and CFS/ME patients [16,123,18], suggesting that compressive MT may provide a therapeutic effect by restoring miRNA levels.

Additional to the compressive component of MT that induces changes in mechano-sensitive receptors, mechanomiRs and other molecules sensitive to this physical input, or effects in the immune and sensorial systems, MT also, inherently, contains an emotional component that is transferred to the patient through mental relaxation by the sense of touch. In fact positive emotional stimulus such as watching humor videos has been reported to increase NK cytotoxic activity only 12

hours after exposure to this stimulus [124]. In another study, a program of 8 weeks consisting of 20-30 minutes/day meditation at home, 6 days/week for mindfulness-based stress reduction (MBSR), showed increased killing activity of NK cells only in subjects reporting an improvement [125]. As stated formerly, animal stroking presented different responses to those elicited only by compression [54]. Also, MT of preterm newborn infants involving low pressures induces a positive effect in weight gain and an increase in vagal tone [126]. These observations indicate that MT protocols may have different effects on different individuals and are context-dependent (operator and environment) leading to heterogeneous responses, a limitation for experimental reproducibility difficult to control.

The state of central sensitivity defined for FM and in general the threshold of hyperalgesia or allodynia for patients in general (i.e. pain induced by touch or massage) may impose limitations to MT therapeutics as certain forces seem to be required to induce molecular changes, and therefore benefits, in animal models [46,67,127]. In fact, by assaying manual forces 0.76 to 4.54 N/cm to obtain hypoalgesic effect McLean et al., concluded that the level of applied force was critical for pain relief setting its value beyond 1.9 N/cm ($P=0.014$) for lateral glide mobilization. Importantly, The intensity of therapeutic forces might be perceived by FM patients as unbearable pain restricting its use, however, as the compressing effects have been shown to be systemic, impacting contralateral not treated limbs, in animals [46,67], MT could be concentrated to particular low pain areas of the body and yet obtain overall pain-reducing benefits.

4. Future directions

The design of effective reproducible MT treatments, in general, relies on the standardization of protocols by rigorously defining compressive and stretching forces, extension of the area treated and frequency of applied movements. The parameters to be set in the protocol should be justified with controlled findings. In this respect animal experimentation is key in determining physiological and molecular changes that associate with treatments. With an interest in identifying potential benefits of MT for the treatment of FM and CFS/ME a review of the impact that MT may have on muscle regeneration, so that deconditioned or atrophied muscles recover, on pain relief and on the immune and neural systems is presented in section 2. of this manuscript. The evidence obtained from animal experimentation using mimetic devices is considered valuable but incomplete. Although the response to MT maneuvers at the molecular level is clear, for example the tolerance associated marker ILT3, which could benefit autoimmune diseases [49] appears induced by medium load pressure treatments [46], and many miRNAs respond to certain compressive loads [73], the current paucity of information limits the potential of adapting MT to particular health problems.

In fact, as of June 30th 2018, the number of studies registered in Pubmed containing “mRNA” and “physiotherapy” terms was 764 versus only 63 for “miRNA” and “physiotherapy” key search words. For the first group, the trend shows a marked increase in the past decade (2009-2017) with 71% of the studies found *vs* only 19% for the previous decade (1998-2008), while in the second group the oldest publication dates of 2008, reflecting a growing interest in evaluating the effects that physiotherapy induces at the molecular level. It will be through the building of databases nurtured with molecular and physiological observations in animals and other experimentation models that researchers will be able to design rational diseased-focused MT-based CTs. The results of CTs importantly will be used for validation and refinement of initial protocols in continuation CTs to unravel optimized effective physiotherapy-based therapeutic programs for particular health problems. Please see below a proposed flow chart for the recommended set of future actions, requiring efforts from multidisciplinary teams, leading to the design of reproducible standardized effective physiotherapy treatments to different disease states by MPTA (Figure 1).




Figure 1. MPTA to define and standardize effective disease-tailored physiotherapy protocols flowchart.

A similar approach to miRDDCR (a miRNA-based method to comprehensively infer drug-disease causal relationships) [128] could be structured to infer MT-disease relationship regardless of biomarker-disease causal effect. As molecular biomarkers of FM and CFS/ME are identified and validated the selection of molecular determinants to monitor effects of MT on these patients will be facilitated. The fact that undamaged muscle tissue responds to a determined physiotherapy program with particular gene expression profiles does not guarantee that damaged or sick tissue will offer an equivalent response. For this reason it results necessary that the evaluation of a treatment includes animal disease models that faithfully replicate the disease. Despite the lack of validated biomarkers for FM and CFS/ME a few animal models have been developed [80, 81] which could be used for comparison.

Some MT-based clinical treatments, as it is the case of deep tissue or cross-friction massage, utilize high force to induce transient local inflammation with the final goal of promoting repair and regeneration [129]. Although a benefit from this approach cannot be completely discarded at this point, a preferential exploration of medium load based MT protocols is recommended for the treatment of FM and CFS/ME with the intention of minimizing patient discomfort while providing health improvements. Massages with soft to moderate pressures, in addition, avoid fatigue after treatment.

An important limitation to be minimized in the design of reproducible optimized standardized MT-protocols based on defined pressure and stretch intensities is the inherent affective or emotional response associated with this type of treatment. Responders to these affective cues could be controlled by applying MT protocols below threshold levels of mechanical response (sham treatments) and considering as placebo responders to these individuals. Placebo responders will be excluded in CTs MPTA-based in an attempt to isolate response to mechanical cues from affective responses (see Figure 1).

As a way to monitor MT success towards setting the criteria for protocol optimization in CTs (validation and refinements steps, Figure 1), concomitant health status of patients with treatment should be evaluated. It would be very helpful for this purpose to count with methods that are minimally invasive at the time that are informative and sensitive. These features are fulfilled by a liquid biopsy approach which usually corresponds to a small amount of blood or other body fluid where biomarker levels can be readily assessed. In the case of FM and CFS/ME which are complex diseases affecting various tissues and systems, an advantageous fluid fraction could correspond to EVs contained in all body fluids so far tested. EVs are a mixture of vesicles with different functions secreted by all cell types. Among them a particular set of vesicles that present with certain markers and which generate from multivesicular bodies in the cell, have attracted special attention of researchers as they have been shown to serve intercellular communication functions [130]. By directional packaging of certain molecules, particularly miRNAs, these exosomes have been shown to spread and maintain disease [130, 131]. The fact that EVs are released from all body tissues into body fluids provides the advantage that their analysis will inform us of the status of organs potentially replacing in the future the need of the traditional invasive solid tissue biopsies. Other assays in body fluids not involving EVs isolation are also available, for example in a study by Arroyo-Morales et al., saliva IgA levels were used to monitor the effects of a 40-minute myofascial induction by MT after exercising in healthy individuals (N=60) [132]. In fact saliva is acquiring importance as a non-invasive method for the diagnosis, prediction and progression of several diseases [133] and could also be an easy way to monitor effectiveness of physiotherapy protocols.

5. Conclusions

In summary, we can conclude that there is an urgency to standardize, control and optimize MT, and physiotherapy protocols in general, as the conflictive results frequently found in the literature may arise from subjective components and the lack of precise parameter definition in their procedures leading to heterogeneity of outcomes. Gene-expression information in relation to defined MT parameters could serve as guidelines for an adequate design of MT therapeutic protocols to be tested and refined through CTs. The potential of microRNA and particularly mechanomiR profiles as an approach to build and monitor MT treatments has been evidenced here. Comparison of results from studies in animal models and MT mimetic devices reviewed, together with FM and CFS/ME patient dysfunctions, points to plausible benefits of MT treatments for these patients. Additionally MT offers a safe alternative to physical exercise for these patients, provided that hyperalgesia and allodynia permits application of effective pressures or stretching forces. However, a more complete view of molecular patterns associated to both, disease and particular MT protocols are required to ensure the development of effective and safe treatments

Acknowledgments: The study was funded by the Fundación Universidad Católica de Valencia San Vicente Mártir (UCV) Research Grant Program. The funders had no role in study design, decision to publish, or preparation of the manuscript.

Author Contributions: J.A.E., M.G-E. and E.O. reviewed the cited literature and wrote the manuscript. E.O. designed the structure of the review and setup guidelines for the writing of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

The following abbreviations are used in this manuscript:

MT: Manual Therapy

FM: Fibromyalgia

CFS/ME: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

MPTA: Molecular Physiotherapy Approach

CCL: Cyclic Compressive Loading

CT: Clinical Trial

miR: microRNA

EV: Extracellular Vesicle

ICD: international Classification of Diseases

PBMC: Peripheral Blood Mononuclear cells

DRG: Dorsal Root Ganglion

SDH: Spinal cord Dorsal Horn

References

- Boerma T, Harrison J, Jakob R, Mathers C, Schmider A, Weber S. Revising the ICD: explaining the WHO approach. *Lancet*. 2016;388(10059):2476-2477. doi: 10.1016/S0140-6736(16)31851-7.
- Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL et al. The American College of Rheumatology 1990 Criteria for the Classification of fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis Rheum*. 1990;33(2):160-72. doi: 10.1002/art.1780330203.
- Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis Care Res (Hoboken)* 2010; 62(5): 600-610. doi: 10.1002/acr.20140.
- Jahan F, Nanji K, Qidwai W, Qasim R. Fibromyalgia syndrome: an overview of pathophysiology, diagnosis and management. *Oman Med J*. 2012;27(3):192-5. doi: 10.5001/omj.2012.44.
- Carruthers BM, Jain, AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner A, et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols. *Journal of Chronic Fatigue Syndrome* 2003;11 (2): 7-115. doi:10.1300/J092v11n01_02
- Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: International Consensus Criteria. *J Intern Med*. 2011;270(4):327-38. doi: 10.1111/j.1365-2796.2011.02428.x.
- Barsky AJ, Borus JF. Functional somatic syndromes. *Ann Intern Med*. 1999; 130(11):910-21.
- Abbi B, Natelson BH. Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the 'single syndrome' hypothesis. *QJM*. 2013;106(1):3-9. doi: 10.1093/qjmed/hcs156.
- Natelson BH, Vu D, Coplan JD, Mao X, Blate M, Kang G, Soto E, Kapusuz T, Shungu DC. Elevations of Ventricular Lactate Levels Occur in Both Chronic Fatigue Syndrome and Fibromyalgia. *Fatigue*. 2017; 5(1):15-20. doi:10.1080/21641846.2017.1280114.
- McManimen SL, Jason LA. Post-Exertional Malaise in Patients with ME and CFS with Comorbid Fibromyalgia. *SRL Neurol Neurosurg*. 2017; 3(1):22-27.
- Naschitz JE, Rozenbaum M, Rosner I, Sabo E, Priselac RM, Shaviv N, et al. Cardiovascular response to upright tilt in fibromyalgia differs from that in chronic fatigue syndrome. *J Rheumatol* 2001; 28:1356-60.
- Naschitz JE, Slobodin G, Sharif D, Fields M, Isseroff H, Sabo E, et al. Electrocardiographic QT interval and cardiovascular reactivity in fibromyalgia differ from chronic fatigue syndrome. *Eur J Intern Med* 2008; 19:187-91. doi: 10.1016/j.ejim.2007.08.003.
- Korszun A, Sackett-Lundeen L, Papadopoulos E, Brucksch C, Masterson L, Engelberg NC, et al. Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. *J Rheumatol* 1999; 26:2675-80. 21.
- Crofford LJ, Young EA, Engleberg NC, Korszun A, Brucksch CB, McClure LA, et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. *Brain Behav Immun* 2004;18:314-25. doi: 10.1016/j.bbi.2003.12.011.
- Light AR, Bateman L, Jo D, Huguen RW, Vanhaisma TA, White AT, Light KC. Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome. *J Intern Med*. 2012;271(1):64-81. doi: 10.1111/j.1365-2796.2011.02405.x.
- Cerda-Olmedo G, Mena-Duran AV, Monsalve V, Oltra E. Identification of a microRNA signature for the diagnosis of fibromyalgia. *PLoS One*. 2015;10(3):e0121903. doi: 10.1371/journal.pone.0121903.
- Masotti A, Baldassarre A, Guzzo MP, Iannuccelli C, Barbato C, Di Franco M. Circulating microRNA Profiles as Liquid Biopsies for the Characterization and Diagnosis of Fibromyalgia Syndrome. *Mol Neurobiol*. 2017;54(9):7129-7136. doi:10.1007/s12035-016-0235-2.
- Petty RD, McCarthy NE, Le Dieu R, Kerr JR. MicroRNAs hsa-miR-99b, hsa-miR-330, hsa-miR-126 and hsa-miR-30c: Potential Diagnostic Biomarkers in Natural Killer(NK) Cells of Patients with Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME). *PLoS One*. 2016; 11(3):e0150904. doi:10.1371/journal.pone.0150904.

19. Brenu EW, Ashton KJ, Batovska J, Staines DR, Marshall-Gradisnik SM. High-throughput sequencing of plasma microRNA in chronic fatigue syndrome/myalgic encephalomyelitis. *PLoS One*. 2014; 9(9):e102783. doi:10.1371/journal.pone.0102783.
20. Kwiatek R. Treatment of fibromyalgia. *Aust Prescr*. 2017;40(5):179-183.doi: 10.18773/austprescr.2017.056.
21. Bruun Wyller V, Bjørneklett A, Brubakk O, Festvåg L, Follestad I, Malt U, et al. Diagnosis and Treatment of Chronic Fatigue Syndrome/Myalgic Encephalopathy (CFS/ME) [Internet]. Oslo,Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2006. Available from <http://www.ncbi.nlm.nih.gov/books/NBK464796/>
22. Smith ME, Haney E, McDonagh M, Pappas M, Daeges M, Wasson N, Fu R, Nelson HD. Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. *Ann Intern Med*. 2015; 162(12):841-50. doi: 10.7326/M15-0114.
23. Oliván-Blázquez B, Herrera-Mercadal P, Puebla-Guedea M, Pérez-Yus MC, Andrés E, Fayed N, et al. Efficacy of memantine in the treatment of fibromyalgia: a double-blind, randomised, controlled trial with 6-month follow-up. *Pain* 2014;155:2517-25.doi:10.1016/j.pain.2014.09.004.
24. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. *Arthritis Rheum* 2005; 52:2495-505.doi: 10.1002/art.21191.
25. Fluge Ø, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D,et al. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. *PLoS One*. 2015;10(7):e0129898.doi:10.1371/journal.pone.0129898.
26. Eaton N, Cabanas H, Balinas C, Klein A, Staines D, Marshall-Gradisnik S. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation. *BMC Pharmacol Toxicol*. 2018;19(1):12. doi: 10.1186/s40360-018-0203-8.
27. Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, et al.; Chronic Fatigue Syndrome AMP-516 Study Group, Mitchell WM. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. *PLoS One*. 2012;7(3):e31334.doi:10.1371/journal.pone.0031334.
28. Bernardy K, Klose P, Busch AJ, Choy EH, Häuser W. Cognitive behavioural therapies for fibromyalgia. *Cochrane Database Syst Rev*. 2013;(9):CD009796.doi: 10.1002/14651858.CD009796.pub2.
29. Busch AJ, Webber SC, Brachaniec M, Bidonde J, Bello-Haas VD, Danyliw AD,et al. Exercise therapy for fibromyalgia. *Curr Pain Headache Rep*. 2011;15(5):358-67. doi:10.1007/s11916-011-0214-2.
30. White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC,et al. PACE trial management group. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomized trial. *Lancet*. 2011; 377(9768):823-36. doi: 10.1016/S0140-6736(11)60096-2.
31. Sharpe M, Goldsmith KA, Johnson AL, Chalder T, Walker J, White PD. Rehabilitative treatments for chronic fatigue syndrome: long-term follow-up from the PACE trial. *Lancet Psychiatry*. 2015; 2(12):1067-74. doi: 10.1016/S2215-0366(15)00317-X.
32. Twisk F. PACE: CBT and GET are not rehabilitative therapies. *Lancet Psychiatry*. 2016; 3(2):e6. doi: 10.1016/S2215-0366(15)00554-4.
33. Wilshire CE, Kindlon T, Courtney R, Matthees A, Tuller D, Geraghty K,et al. Rethinking the treatment of chronic fatigue syndrome-a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT. *BMC Psychol*. 2018;6(1):6.doi: 10.1186/s40359-018-0218-3.
34. Eller-Smith OC, Nicol AL, Christianson JA. Potential Mechanisms Underlying Centralized Pain and Emerging Therapeutic Interventions. *Front Cell Neurosci*. 2018;12:35.doi: 10.3389/fncel.2018.00035.
35. Li YH, Wang FY, Feng CQ, Yang XF, Sun YH. Massage therapy for fibromyalgia: a systematic review and meta-analysis of randomized controlled trials. *PLoS One*. 2014;9(2):e89304. doi: 10.1371/journal.pone.0089304.
36. Yuan SL, Matsutani LA, Marques AP. Effectiveness of different styles of massage therapy in fibromyalgia: a systematic review and meta-analysis. *Man Ther*. 2015;20(2):257-64. doi: 10.1016/j.math.2014.09.003.
37. Alraek T, Lee MS, Choi TY, Cao H, Liu J. Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review. *BMC Complement Altern Med*. 2011; 11:87. doi: 10.1186/1472-6882-11-87.

38. Field TM, Sunshine W, Hernandez-Reif M, Quintino O, Schanberg S, Kuhn C, et al. Massage therapy effects on depression and somatic symptoms in chronic fatigue syndrome. *J Chronic Fatigue Syndr* 1997; 3:43-51. doi: 10.1300/J092v03n03_03.
39. Wang JH, Chai TQ, Lin GH, Luo L: Effects of the intelligent-turtle massage on the physical symptoms and immune functions in patients with chronic fatigue syndrome. *J Tradit Chin Med* 2009; 29(1):24-28.doi: 10.1016/S0254-6272(09)60026-1.
40. Thomas E, Bianco A, Paoli A, Palma A. The Relation Between Stretching Typology and Stretching Duration: The Effects on Range of Motion. *Int J Sports Med.* 2018;39(4):243-254. doi: 10.1055/s-0044-101146.
41. Cafarelli E, Flint F. The role of massage in preparation for and recovery from exercise. An overview. *Sports Med.* 1992;14(1):1-9. doi: 10.2165/00007256-199214010-00001.
42. Field T, Diego M, Hernandez-Reif M. Moderate pressure is essential for massage therapy effects. *Int J Neurosci.* 2010;120(5):381-5. doi:10.3109/00207450903579475.
43. Field T, Hernandez-Reif M, Diego M, Schanberg S, Kuhn C. Cortisol decreases and serotonin and dopamine increase following massage therapy. *Int J Neurosci.* 2005;115(10):1397-413.doi: 10.1080/0020745050956459.
44. Kumar A, Chaudhry I, Reid MB, Boriak AM. Distinct signaling pathways are activated in response to mechanical stress applied axially and transversely to skeletal muscle fibers. *J Biol Chem.* 2002;277(48):46493-503. doi: 10.1186/1471-2121-10-52.
45. Kumar A, Boriak AM. Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. *FASEB J.* 2003;17(3):386-96. doi: 10.1096/fj.02-0542.
46. Waters-Banker C, Butterfield TA, Dupont-Versteegden EE. Immunomodulatory effects of massage on nonperturbed skeletal muscle in rats. *J Appl Physiol* (1985). 2014;116(2):164-75.doi: 10.1152/japplphysiol.00573.2013.
47. Martinez CO, McHale MJ, Wells JT, Ochoa O, Michalek JE, McManus LM, et al. Regulation of skeletal muscle regeneration by CCR2-activating chemokines is directly related to macrophage recruitment. *Am J Physiol Regul Integr Comp Physiol.* 2010;299(3):R832-42.doi: 10.1152/ajpregu.00797.2009.
48. Pillon NJ, Bilan PJ, Fink LN, Klip A. Cross-talk between skeletal muscle and immune cells: muscle-derived mediators and metabolic implications. *Am J Physiol Endocrinol Metab.* 2013;304(5):E453-65. doi: 10.1152/ajpendo.00553.2012.
49. Cousens L, Najafian N, Martin WD, De Groot AS. Tregitope: Immunomodulation powerhouse. *Hum Immunol.* 2014;75(12):1139-46. doi:10.1016/j.humimm.2014.10.012.
50. Schröder B. The multifaceted roles of the invariant chain CD74--More than just a chaperone. *Biochim Biophys Acta.* 2016;1863(6 Pt A):1269-81. doi:10.1016/j.bbamcr.2016.03.026.
51. Lee M, Kovacs-Nolan J, Yang C, Archbold T, Fan MZ, Mine Y. Hen egg lysozyme attenuates inflammation and modulates local gene expression in a porcine model of dextran sodium sulfate (DSS)-induced colitis. *J Agric Food Chem.* 2009;57(6):2233-40.doi: 10.1021/jf803133b.
52. Saclier M, Cuvellier S, Magnan M, et al. Monocyte/macrophage interactions with myogenic precursor cells during skeletal muscle regeneration. *FEBS J.* 2013;280:4118e4130.doi: 10.1111/febs.12166.
53. Lu H, Huang D, Ransohoff RM, Zhou L. Acute skeletal muscle injury: CCL2 expression by both monocytes and injured muscle is required for repair. *FASEB J.* 2011;25(10):3344-55.doi: 10.1096/fj.10-178939.
54. Major B, Rattazzi L, Brod S, Pilipović I, Leposavić G, D'Acquisto F. Massage-like stroking boosts the immune system in mice. *Sci Rep.* 2015; 5:10913. doi: 10.1038/srep10913.
55. Dodge T, Wanis M, Ayoub R, Zhao L, Watts NB, Bhattacharya A, et al. Mechanical loading, damping, and load-driven bone formation in mouse tibiae. *Bone.* 2012;51(4):810-8.doi: 10.1016/j.bone.2012.07.021.
56. Zhang P, Hamamura K, Turner CH, Yokota H. Lengthening of mouse hindlimbs with joint loading. *J Bone Miner Metab.* 2010;28(3):268-75. doi:10.1007/s00774-009-0135-x.
57. Shim JW, Dodge TR, Hammond MA, Wallace JM, Zhou FC, Yokota H. Physical weight loading induces expression of tryptophan hydroxylase 2 in the brain stem. *PLoS One.* 2014;9(1):e85095. doi: 10.1371/journal.pone.0085095.
58. Mattson MP, Duan W, Wan R, Guo Z. Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. *NeuroRx.* 2004;1(1):111-6. doi: 10.1602/neurorx.1.1.111.
59. Ma Q. Beneficial effects of moderate voluntary physical exercise and its biological mechanisms on brain health. *Neurosci Bull.* 2008;24(4):265-70.doi:10.1007/s12264-008-0402-1.

60. Park K, Lee S, Hong Y, Park S, Choi J, Chang KT, Kim JH, Hong Y. Therapeutic physical exercise in neural injury: friend or foe? *J Phys Ther Sci.* 2015;27(12):3933-5. doi: 10.1589/jpts.27.3933.
61. Ottenhof KW, Sild M, Lévesque ML, Ruhé HG, Booi L. TPH2 polymorphisms across the spectrum of psychiatric morbidity: A systematic review and meta-analysis. *Neurosci Biobehav Rev.* 2018;92:29-42. doi:10.1016/j.neubiorev.2018.05.018.
62. Matthes S, Mosienko V, Bashammakh S, Alenina N, Bader M. Tryptophan hydroxylase as novel target for the treatment of depressive disorders. *Pharmacology.* 2010;85(2):95-109. doi: 10.1159/000279322.
63. Švob Štrac D, Pivac N, Mück-Šeler D. The serotonergic system and cognitive function. *Transl Neurosci.* 2016;7(1):35-49. doi: 10.1515/tnsci-2016-0007.
64. Cezar CA, Roche ET, Vandeburgh HH, Duda GN, Walsh CJ, Mooney DJ. Biologic-free mechanically induced muscle regeneration. *Proc Natl Acad Sci U S A.* 2016;113(6):1534-9. doi: 10.1073/pnas.1517517113.
65. Borselli C, Storrie H, Benesch-Lee F, Shvartsman D, Cezar C, Lichtman JW, et al. Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. *Proc Natl Acad Sci U S A.* 2010;107(8):3287-92. doi: 10.1073/pnas.0903875106.
66. Tatsumi R. Mechano-biology of skeletal muscle hypertrophy and regeneration: possible mechanism of stretch-induced activation of resident myogenic stem cells. *Anim Sci J.* 2010;81(1):11-20. doi: 10.1111/j.1740-0929.2009.00712.x.
67. Miller BF, Hamilton KL, Majeed ZR, Abshire SM, Confides AL, Hayek AM, et al. Enhanced skeletal muscle regrowth and remodelling in massaged and contralateral non-massaged hindlimb. *J Physiol.* 2018;596(1):83-103. doi:10.1113/JP275089.
68. Wu R, Li H, Zhai L, Zou X, Meng J, Zhong R, Li C, Wang H, Zhang Y, Zhu D. MicroRNA-431 accelerates muscle regeneration and ameliorates muscular dystrophy by targeting Pax7 in mice. *Nat Commun.* 2015;6:7713. doi: 10.1038/ncomms8713. PubMed PMID: 26151913.
69. Wu D, Murashov AK. MicroRNA-431 regulates axon regeneration in mature sensory neurons by targeting the Wnt antagonist Kremen1. *Front Mol Neurosci.* 2013;6:35. doi: 10.3389/fnmol.2013.00035.
70. Luan Z, Liu Y, Stuhlmiller TJ, Marquez J, García-Castro MI. SUMOylation of Pax7 is essential for neural crest and muscle development. *Cell Mol Life Sci.* 2013;70(10):1793-806. doi: 10.1007/s00018-012-1220-1.
71. Griffiths-Jones S. The microRNA Registry. *Nucleic Acids Res.* 2004;32(Database issue):D109-11. doi:10.1093/nar/gkh023.
72. Tétreault N, De Guire V. miRNAs: their discovery, biogenesis and mechanism of action. *Clin Biochem.* 2013;46(10-11):842-5. doi:10.1016/j.clinbiochem.2013.02.009.
73. Mohamed JS, Hajira A, Lopez MA, Boriek AM. Genome-wide Mechanosensitive MicroRNA (MechanomiR) Screen Uncovers Dysregulation of Their Regulatory Networks in the mdm Mouse Model of Muscular Dystrophy. *J Biol Chem.* 2015;290(41):24986-5011. doi: 10.1074/jbc.M115.659375.
74. Ladoux B, Nelson WJ, Yan J, Mège RM. The mechanotransduction machinery at work at adherens junctions. *Integr Biol (Camb).* 2015;7(10):1109-19. doi:10.1039/c5ib00070j.
75. Huang Y, Crawford M, Higuera-Castro N, Nana-Sinkam P, Ghadiali SN. miR-146a regulates mechanotransduction and pressure-induced inflammation in small airway epithelium. *FASEB J.* 2012;26(8):3351-64. doi: 10.1096/fj.11-199240.
76. Kobus K, Kopycinska J, Kozłowska-Wiechowska A, Urasinska E, Kempinska-Podhorodecka A, Haas TL et al. Angiogenesis within the duodenum of patients with cirrhosis is modulated by mechanosensitive Kruppel-like factor 2 and microRNA-126. *Liver Int.* 2012;32(8):1222-32. doi:10.1111/j.1478-3231.2012.02791.x.
77. Drummond MJ, McCarthy JJ, Sinha M, Spratt HM, Volpi E, Esser KA, et al. Aging and microRNA expression in human skeletal muscle: a microarray and bioinformatics analysis. *Physiol Genomics.* 2011;43(10):595-603. doi:10.1152/physiolgenomics.00148.2010.
78. von Frey M. On the Use of Stimulus Hairs. 1896:71-131.
79. Gregory NS, Harris AL, Robinson CR, Dougherty PM, Fuchs PN, Sluka KA. An overview of animal models of pain: disease models and outcome measures. *J Pain.* 2013;14(11):1255-69. doi: 10.1016/j.jpain.2013.06.008.
80. DeSantana JM, da Cruz KM, Sluka KA. Animal models of fibromyalgia. *Arthritis Res Ther.* 2013;15(6):222. doi: 10.1186/ar4402.

81. Yasui M, Yoshimura T, Takeuchi S, Tokizane K, Tsuda M, Inoue K, et al. A chronic fatigue syndrome model demonstrates mechanical allodynia and muscular hyperalgesia via spinal microglial activation. *Glia*. 2014;62(9):1407-17. doi:10.1002/glia.22687.
82. Aldrich BT, Frakes EP, Kasuya J, Hammond DL, Kitamoto T. Changes in expression of sensory organ-specific microRNAs in rat dorsal root ganglia in association with mechanical hypersensitivity induced by spinal nerve ligation. *Neuroscience*. 2009;164(2):711-23. doi: 10.1016/j.neuroscience.2009.08.033.
83. Lin CR, Chen KH, Yang CH, Huang HW, Sheen-Chen SM. Intrathecal miR-183 delivery suppresses mechanical allodynia in mononeuropathic rats. *Eur J Neurosci*. 2014;39(10):1682-9. doi: 10.1111/ejn.12522.
84. Tam Tam S, Bastian I, Zhou XF, Vander Hoek M, Michael MZ, Gibbins IL, et al. MicroRNA-143 expression in dorsal root ganglion neurons. *Cell Tissue Res*. 2011;346(2):163-73. doi: 10.1007/s00441-011-1263-x.
85. Bali KK, Selvaraj D, Satagopam VP, Lu J, Schneider R, Kuner R. Genome-wide identification and functional analyses of microRNA signatures associated with cancer pain. *EMBO Mol Med*. 2013;5(11):1740-58. doi: 10.1002/emmm.201302797.
86. von Schack D, Agostino MJ, Murray BS, Li Y, Reddy PS, Chen J, et al. Dynamic changes in the microRNA expression profile reveal multiple regulatory mechanisms in the spinal nerve ligation model of neuropathic pain. *PLoS One*. 2011;6(3):e17670. doi:10.1371/journal.pone.0017670.
87. Ren K, Dubner R. Interactions between the immune and nervous systems in pain. *Nat Med*. 2010;16(11):1267-76. doi: 10.1038/nm.2234.
88. Brenu E W, Ashton K J, van Driel M, Staines D R, Peterson D, Atkinson G M, et al. Cytotoxic lymphocyte microRNAs as prospective biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis. *Journal of affective disorders*. 2012;141(2):261-269. doi: 10.1016/j.jad.2012.03.037.
89. Yamasaki K, Nakasa T, Miyaki S, Ishikawa M, Deie M, Adachi N, et al. Expression of MicroRNA-146a in osteoarthritis cartilage. *Arthritis Rheum*. 2009;60(4):1035-41. doi: 10.1002/art.24404.
90. Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. *Arthritis Rheum*. 2008;58(5):1284-92. doi: 10.1002/art.23429.
91. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. *Proc Natl Acad Sci U S A*. 2006;103(33):12481-6.
92. Li X, Gibson G, Kim JS, Kroin J, Xu S, van Wijnen AJ, Im HJ. MicroRNA-146a is linked to pain-related pathophysiology of osteoarthritis. *Gene*. 2011;480(1-2):34-41. doi: 10.1016/j.gene.2011.03.003.
93. Bjersing J L, Lundborg C, Bokarewa M I, Mannerkorpi K. Profile of cerebrospinal microRNAs in fibromyalgia. *PLoS One*. 2013;8(10), e78762. doi: 10.1371/journal.pone.0078762.
94. Nakanishi K, Nakasa T, Tanaka N, Ishikawa M, Yamada K, Yamasaki K, et al. Responses of microRNAs 124a and 223 following spinal cord injury in mice. *Spinal Cord*. 2010;48(3):192-6. doi:10.1038/sc.2009.89.
95. Bhalala OG, Pan L, Sahni V, McGuire TL, Gruner K, Tourtellotte WG, et al. microRNA-21 regulates astrocytic response following spinal cord injury. *J Neurosci*. 2012;32(50):17935-47. doi: 10.1523/JNEUROSCI.3860-12.2012.
96. Poh KW, Yeo JF, Ong WY. MicroRNA changes in the mouse prefrontal cortex after inflammatory pain. *Eur J Pain*. 2011;15(8):801.e1-12. doi:10.1016/j.ejpain.2011.02.002.
97. Simeoli R, Montague K, Jones HR, Castaldi L, Chambers D, Kelleher JH, et al. Exosomal cargo including microRNA regulates sensory neuron to macrophage communication after nerve trauma. *Nat Commun*. 2017;8(1):1778. doi: 10.1038/s41467-017-01841-5.
98. Jiang S, Zhang H, Fang M, Zhang Y, Lu N, Zhu Q, et al. Analgesic effects of Chinese Tuina massage in a rat model of pain. *Exp Ther Med*. 2016;11(4):1367-1374. doi: 10.3892/etm.2016.3055.
99. Terry R, Perry R, Ernst E. An overview of systematic reviews of complementary and alternative medicine for fibromyalgia. *Clin Rheumatol*. 2012;31(1):55-66. doi: 10.1007/s10067-011-1783-5.
100. Kalichman L. Massage therapy for fibromyalgia symptoms. *Rheumatol Int*. 2010;30(9):1151-7. doi: 10.1007/s00296-010-1409-2.
101. Winkelmann A, Häuser W, Friedel E, Moog-Egan M, Seeger D, Settan M, et al. [Physiotherapy and physical therapies for fibromyalgia syndrome. Systematic review, meta-analysis and guideline]. *Schmerz*. 2012;26(3):276-86. doi: 10.1007/s00482-012-1171-3.
102. Terhorst L, Schneider MJ, Kim KH, Goozdich LM, Stilley CS. Complementary and alternative medicine in the treatment of pain in fibromyalgia: a systematic review of randomized controlled trials. *J Manipulative Physiol Ther*. 2011;34(7):483-96. doi: 10.1016/j.jmpt.2011.05.006.

103. Bronfort G, Haas M, Evans R, Leininger B, Triano J. Effectiveness of manual therapies: the UK evidence report. *Chiropr Osteopat.* 2010;18:3. doi:10.1186/1746-1340-18-3.
104. Crawford C, Boyd C, Paat CF, Price A, Xenakis L, Yang E, et al. Evidence for Massage Therapy (EMT) Working Group . The Impact of Massage Therapy on Function in Pain Populations-A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part I, Patients Experiencing Pain in the General Population. *Pain Med.* 2016;17(7):1353-1375. doi: 10.1093/pm/pnw099.
105. Dupuy O, Douzi W, Theurot D, Bosquet L, Dugué B. An Evidence-Based Approach for Choosing Post-exercise Recovery Techniques to Reduce Markers of Muscle Damage, Soreness, Fatigue, and Inflammation: A Systematic Review With Meta-Analysis. *Front Physiol.* 2018;9:403. doi: 10.3389/fphys.2018.00403.
106. Crane JD, Ogborn DI, Cupido C, Melov S, Hubbard A, Bourgeois JM, et al. Massage therapy attenuates inflammatory signaling after exercise-induced muscle damage. *Sci Transl Med.* 2012;4(119):119ra13. doi:10.1126/scitranslmed.3002882.
107. Tsilioni I, Russell IJ, Stewart JM, Gleason RM, Theoharides TC. Neuropeptides CRH, SP, HK-1, and Inflammatory Cytokines IL-6 and TNF Are Increased in Serum of Patients with Fibromyalgia Syndrome, Implicating Mast Cells. *J Pharmacol Exp Ther.* 2016;356(3):664-72. doi: 10.1124/jpet.115.230060.
108. Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. *Clin Infect Dis.* 1994;18 Suppl 1:S147-53.
109. Delextrat A, Hippocrate A, Ledington-Wright S, Clarke ND. Including stretches to a massage routine improves recovery from official matches in basketball players. *J Strength Cond Res.* 2014;28(3):716-27. doi:10.1519/JSC.0b013e3182aa5e7c. PubMed PMID: 24561594.
110. Rowe PC, Fontaine KR, Violland RL. Neuromuscular strain as a contributor to cognitive and other symptoms in chronic fatigue syndrome: hypothesis and conceptual model. *Front Physiol.* 2013;4:115. doi:10.3389/fphys.2013.00115.
111. Rowe PC, Fontaine KR, Lauver M, Jasion SE, Marden CL, Moni M, et al. Neuromuscular Strain Increases Symptom Intensity in Chronic Fatigue Syndrome. *PLoS One.* 2016;11(7):e0159386. doi:10.1371/journal.pone.0159386.
112. Goats GC. Massage--the scientific basis of an ancient art: Part 2. Physiological and therapeutic effects. *Br J Sports Med.* 1994;28(3):153-6. doi: 10.1136/bjism.28.3.153.
113. Vallelunga A, Berlingieri C, Ragusa M, Purrello M, Stabile MR, Calabrese MC, et al. Physical rehabilitation modulates microRNAs involved in multiple sclerosis: a case report. *Clin Case Rep.* 2017;5(12):2040-2043. doi: 10.1002/ccr3.1100.
114. Bjersing JL, Bokarewa MI, Mannerkorpi K. Profile of circulating microRNAs in fibromyalgia and their relation to symptom severity: an exploratory study. *Rheumatol Int.* 2015;35(4):635-42. doi: 10.1007/s00296-014-3139-3.
115. Citak-Karakaya I, Akbayrak T, Demirtürk F, Ekici G, Bakar Y. Short and long-term results of connective tissue manipulation and combined ultrasound therapy in patients with fibromyalgia. *J Manipulative Physiol Ther.* 2006;29(7):524-8. doi: 10.1016/j.jmpt.2006.06.019.
116. Sagar SM, Dryden T, Wong RK. Massage therapy for cancer patients: a reciprocal relationship between body and mind. *Curr Oncol.* 2007;14(2):45-56. doi: 10.3747/co.2007.105.
117. Goldberg J, Sullivan SJ, Seaborne DE. The effect of two intensities of massage on H-reflex amplitude. *Phys Ther.* 1992;72(6):449-57. doi: 10.1093/ptj/72.6.449.
118. Lidbeck J. Central hyperexcitability in chronic musculoskeletal pain: a conceptual breakthrough with multiple clinical implications. *Pain Res Manag.* 2002;7(2):81-92. doi:
119. Langevin HM, Bouffard NA, Badger GJ, Iatridis JC, Howe AK. Dynamic fibroblast cytoskeletal response to subcutaneous tissue stretch ex vivo and in vivo. *Am J Physiol Cell Physiol* 2005;288:C747-56. doi: 10.1152/ajpcell.00420.2004.
120. Kaada B, Torsteinbø O. Increase of plasma beta-endorphins in connective tissue massage. *Gen Pharmacol.* 1989;20(4):487-9. doi: 10.1016/0306-3623(89)90200-0.
121. Roberts L. Effects of patterns of pressure application on resting electromyography during massage. *Int J Ther Massage Bodywork.* 2011; 4(1):4-11. doi: 10.1037/0003-066X.53.12.1270.

122. Rullman E, Mekjavic IB, Fischer H, Eiken O. PlanHab (Planetary Habitat Simulation): the combined and separate effects of 21 days bed rest and hypoxic confinement on human skeletal muscle miRNA expression. *Physiol Rep.* 2016;4(8). pii: e12753. doi: 10.14814/phy2.12753.
123. Masotti A, Baldassarre A, Guzzo MP, Iannuccelli C, Barbato C, Di Franco M. Circulating microRNA Profiles as Liquid Biopsies for the Characterization and Diagnosis of Fibromyalgia Syndrome. *Mol Neurobiol.* 2017;54(9):7129-7136. doi:10.1007/s12035-016-0235-2.
124. Berk LS, Felten DL, Tan SA, Bittman BB, Westengard J. Modulation of neuroimmune parameters during the eustress of humor-associated mirthful laughter. *Altern Ther Health Med.* 2001;7(2):62-72, 74-6.
125. Fang CY, Reibel DK, Longacre ML, Rosenzweig S, Campbell DE, Douglas SD. Enhanced psychosocial well-being following participation in a mindfulness-based stress reduction program is associated with increased natural killer cell activity. *J Altern Complement Med.* 2010;16(5):531-8. doi:10.1089/acm.2009.0018.
126. Niemi AK. Review of Randomized Controlled Trials of Massage in Preterm Infants. *Children (Basel).* 2017;4(4). pii: E21. doi:10.3390/children4040021.
127. McLean S, Naish R, Reed L, Urry S, Vicenzino B. A pilot study of the manual force levels required to produce manipulation induced hypoalgesia. *Clin Biomech (Bristol, Avon).* 2002;17(4):304-8. doi:10.1016/S0268-0033(02)00017-7.
128. Chen H, Zhang Z, Peng W. miRDDCR: a miRNA-based method to comprehensively infer drug-disease causal relationships. *Sci Rep.* 2017;7(1):15921. doi:10.1038/s41598-017-15716-8.
129. Pitt JM, Kroemer G, Zitvogel L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. *J Clin Invest.* 2016;126(4):1139-43. doi: 10.1172/JCI87316.
130. Farasyn A. Release of myofascial pain with deep cross-friction named "roptrotherapy". *Int J Ther Massage Bodywork.* 2010 Mar 17;3(1):36-7. doi.org/10.3822/ijtmb.v3i1.77.
131. Oltra E. Relevance of splicing on tumor-released exosome landscape: implications in cancer therapeutics. *Front Endocrinol (Lausanne).* 2014;5:194. doi: 10.3389/fendo.2014.00194.
132. Arroyo-Morales M, Olea N, Ruíz C, del Castillo Jde D, Martínez M, Lorenzo C, et al. Massage after exercise--responses of immunologic and endocrine markers: a randomized single-blind placebo-controlled study. *J Strength Cond Res.* 2009;23(2):638-44. doi: 10.1519/JSC.0b013e318196b6a6.
133. Gutiérrez-Corrales A, Campano-Cuevas E, Castillo-Dalí G, Torres-Lagares D, Gutiérrez-Pérez JL. Ability of salivary biomarkers in the prognostic of systemic and buccal inflammation. *J Clin Exp Dent.* 2017;9(5):e716-e722. doi:10.4317/jced.53776.